Baseline Moderators of Response to Naltrexone and Bupropion in the Treatment of Methamphetamine Use Disorder: An ADAPT-2 Study.

Journal: Journal of addiction medicine
Published Date: Jul 8, 2025

Abstract

OBJECTIVES: Extended-release naltrexone and once-daily bupropion (NTX-BUP) reduced methamphetamine (MA) use in the Accelerated Development of Additive Pharmacotherapy Treatment for Methamphetamine Use Disorder (ADAPT-1, ADAPT-2) trials. Using a proof-of-concept machine learning technique, we created a classification rule using baseline characteristics to identify individuals who would benefit more from NTX-BUP than from placebo (NTX-BUP-preferred).

Authors

  • Thomas Carmody
    Department of Health Data Science and Biostatistics, Peter O'Donnell Jr. School of Public Health, University of Texas Southwestern Medical Center, Dallas, TX (TC); Center for Depression Research and Clinical Care, Peter O'Donnell Jr. Brain Institute and Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX (TC, TLM, MKJ, MHT); Department of Psychiatry and Biobehavioral Sciences, Department of Family Medicine, University of California Los Angeles, CA (SS).
  • Taryn L Mayes
  • Manish K Jha
  • Steven Shoptaw
  • Madhukar H Trivedi
    Department of Psychiatry, UT Southwestern, Dallas, TX, USA.

Keywords

No keywords available for this article.

External Resources

Popular Topics
Recent Journals